RonacMamtaniMDMSCE
Oncology • Philadelphia, PAAssistant Professor, Medicine, Perelman School of Medicine
Dr. Mamtani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
2 West
Philadelphia, PA 19104Phone+1 215-615-5858Fax+1 212-746-6692
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
Stony Brook University Health Sciences Center School of MedicineClass of 2006
Certifications & Licensure
PA State Medical License 2009 - 2026
NY State Medical License 2008 - 2010- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Evolving racial/ethnic disparities in AML survival in the novel therapy era.Xin Wang, Phyllis A Gimotty, Andrew H Matthews, Ronac Mamtani, Selina M Luger
Blood Advances. 2025-02-11 - Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.Ronac Mamtani, Nobuaki Matsubara, Alvaro Montesa Pino, Urbano Anido Herranz, Mehmet A N Şendur
Clinical Genitourinary Cancer. 2025-02-01 - Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations.Xavier Orcutt, Kan Chen, Ronac Mamtani, Qi Long, Ravi B Parikh
Nature Medicine. 2025-01-03
Journal Articles
- Cisplatin Versus Cetuximab with Definitive Concurrent Radiotherapy for Head and Neck Squamous Cell Carcinoma: An Analysis of Veterans Health Affairs DataRavi Vinnakota, Keith Sigel, Joshua M Bauml, Roger B Cohen, Nevena Damjanov, Corey J Langer, Ronac Mamtani, Charu Aggarwal, Christina Knepley, Juan Wisnivesky, Cancer
Authored Content
- A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018
- A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018
- A New Look at the International Duration Evaluation of Adjuvant Therapy (IDEA) Classification—Defining Novel Predictive and Prognostic Markers in Stage III Colon CancerMay 2018
Press Mentions
Last Year's Platinum-Based Drugs Shortage Didn't Raise Cancer Deaths, Study FoundDecember 24th, 2024- Platinum Chemotherapy Drugs' Shortages and Cancer MortalityDecember 14th, 2024
- Shortages of Generic Platinum Chemotherapy Did Not Result in an Increase in DeathsDecember 14th, 2024
- Join now to see all
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
